CSL Limited
CSL
Rankning i aktier
#363
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Aktiekurs
$138.45
Marknadsvärde
$66.44B
Förändring (1 dag)
0.62%
Förändring (1 år)
-2.39%
Land
AU
Handel CSL Limited (CSL)
Kategori
Healthcare
Vinst för CSL Limited (CSL)
Vinst i Jun 2026 TTM: $-4.02B
Enligt de senaste finansiella rapporterna från CSL Limited är företagets nuvarande vinst $-4.02B. År 2024 hade företaget en vinst på $3.38B, en ökning jämfört med vinsten år 2023 som var $2.66B. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för CSL Limited från 2000 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $-4.02B | -207.85% |
| 2025 | $3.72B | 10.34% |
| 2024 | $3.38B | 26.74% |
| 2023 | $2.66B | -4.19% |
| 2022 | $2.78B | -6.80% |
| 2021 | $2.98B | 15.92% |
| 2020 | $2.57B | 9.89% |
| 2019 | $2.34B | 2.63% |
| 2018 | $2.28B | 35.00% |
| 2017 | $1.69B | 8.61% |
| 2016 | $1.56B | -9.22% |
| 2015 | $1.71B | 6.84% |
| 2014 | $1.60B | 19.64% |
| 2013 | $1.34B | 5.36% |
| 2012 | $1.27B | -7.31% |
| 2011 | $1.37B | 38.29% |
| 2010 | $992.87M | 11.00% |
| 2009 | $894.45M | 2.37% |
| 2008 | $873.74M | 56.73% |
| 2007 | $557.47M | 493.43% |
| 2006 | $93.94M | -74.77% |
| 2005 | $372.39M | 201.20% |
| 2004 | $123.64M | 168.99% |
| 2003 | $45.96M | -7.38% |
| 2002 | $49.63M | -8.38% |
| 2001 | $54.17M | 88.04% |
| 2000 | $28.81M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $5.27B | -231.34% |
US
|
|
| $-3.09B | -23.14% |
US
|
|
| - | - |
CH
|
|
| $1.95B | -148.57% |
NL
|
|
| $3.01B | -174.84% |
BE
|
